United States : CONTRACT with INVAP to design its Florida medical isotope production is signed by Coqui RadioPharma.
Coqui RadioPharmaceuticals Corp., a medical isotope company working to become the first US commercial producer of Molybdenum-99 (Mo-99), has officially inked a contract with INVAP to design its Medical Isotope Production Facility (MIPF) in Alachua, Florida. Mo-99 is the parent isotope of Technetium-99, which is used in 80 % of nuclear medicine procedures worldwide.
Congress in 2012 passed legislation making it a national priority to produce Mo-99, an isotope essential to notice a wide range of diseases, together with cardiovascular disease and cancer.
Argentine nuclear engineering firm INVAP has been concerned in nuclear development for above 30 years. In that time it has worked on above 15 nuclear reactors and associated facilities across the world, together with several reactors used to produce medical isotopes. Among these is the OPAL reactor in Australia, the ETRR-2 reactor in Egypt, and the NUR reactor in Algeria. Coqui Pharma's MIPF will use an open pool reactor technology similar to that employed in the INVAP-designed OPAL facility in Australia.
Carmen I. Bigles, Coqui Pharma president and chief executive officer said, "The signing of this contract cements a key step in implementing proven technology to produce Mo-99 for patients requiring lifesaving medical diagnostics". "Today, Coqui Pharma together with INVAP has built a bridge between the US and Argentina, uniting our efforts to ensure the availability and reliability of the most essential radioisotope in nuclear medicine and with the added benefit of making the world a safer place for generations to come by utilising proven non-proliferation, low-enriched uranium technologies."
Coqui Pharma is getting ready its construction permit application for submission to the US Nuclear Regulatory Commission. Coqui Pharma will make use of present commercially proven technology with tested designs to license and build a facility that has the capability of reliably supplying a large portion of the US market and international needs.
Because of recent and future projected shortages, the issue of US domestic medical isotope production has been talked about at great length within the industry and US. federal government. Coqui Pharma reviewed options obtainable to manufacture Mo-99 and decided that only the INVAP process offers a real, tangible and reliable solution to resolve the medical isotope crisis.
2014 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. ( Syndigate.info ).
|Printer friendly Cite/link Email Feedback|
|Date:||Nov 25, 2014|
|Previous Article:||United States : Infoblox Introduces Free Product Evaluation to Find the DNS Footprints of Cybercrime inside Enterprise Networks.|
|Next Article:||United States : Hitachi data systems and verizon pave the way to simplify enterprise hybrid cloud solutions.|